Miguel Mansilla-Polo, Martí Pons-Benavent, Pablo Fernández-Crehuet, Eva Vilarrasa, Cristina Albanell-Fernández, Enrico Morales-Tedone, Francisca Rausell-Félix, Rebeca Alcalá-García, María Matellanes-Palacios, Gemma Martín-Ezquerra, Fernando Alfageme, Cristina Ciudad-Blanco, María Teresa López-Villaescusa, Patricia Garbayo-Salmons, Antonio Martorell, Begoña Escutia-Muñoz, Fernando Navarro-Blanco, Daniel Martín-Torregrosa, Carlos Cuenca-Barrales, Alejandro Molina-Leyva, Rafael Botella-Estrada
{"title":"比美单抗治疗化脓性扁桃体炎的实际有效性和安全性：一项前瞻性观察研究。","authors":"Miguel Mansilla-Polo, Martí Pons-Benavent, Pablo Fernández-Crehuet, Eva Vilarrasa, Cristina Albanell-Fernández, Enrico Morales-Tedone, Francisca Rausell-Félix, Rebeca Alcalá-García, María Matellanes-Palacios, Gemma Martín-Ezquerra, Fernando Alfageme, Cristina Ciudad-Blanco, María Teresa López-Villaescusa, Patricia Garbayo-Salmons, Antonio Martorell, Begoña Escutia-Muñoz, Fernando Navarro-Blanco, Daniel Martín-Torregrosa, Carlos Cuenca-Barrales, Alejandro Molina-Leyva, Rafael Botella-Estrada","doi":"10.1111/ajd.14339","DOIUrl":null,"url":null,"abstract":"<p><p>In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.</p>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study.\",\"authors\":\"Miguel Mansilla-Polo, Martí Pons-Benavent, Pablo Fernández-Crehuet, Eva Vilarrasa, Cristina Albanell-Fernández, Enrico Morales-Tedone, Francisca Rausell-Félix, Rebeca Alcalá-García, María Matellanes-Palacios, Gemma Martín-Ezquerra, Fernando Alfageme, Cristina Ciudad-Blanco, María Teresa López-Villaescusa, Patricia Garbayo-Salmons, Antonio Martorell, Begoña Escutia-Muñoz, Fernando Navarro-Blanco, Daniel Martín-Torregrosa, Carlos Cuenca-Barrales, Alejandro Molina-Leyva, Rafael Botella-Estrada\",\"doi\":\"10.1111/ajd.14339\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.</p>\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/ajd.14339\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.14339","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study.
In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.
期刊介绍：
Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
